Pharmacyclics Signs US$975 M Agreement with Janssen Biotech for Mid-Stage Btk Inhibitor
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)
Published: 6 Jan-2012
DOI: 10.3833/pdr.v2012.i1.1645 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Pharmacyclics has entered into a global partnership with Johnson & Johnson’s Janssen Biotech unit for its mid-stage haematological cancer programme, PCI-32765...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS